好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Do Sleep Scales Correlate with Pulmonary Function in ALS? Results From the ALS Nutrition/NIPPV Study Group
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (5:30 PM-6:30 PM)
12-007
To examine whether the responses to standard sleep questionnaires used in ALS correlate with measures of pulmonary function.

Presently, NIV is initiated in ALS when FVC falls below 50% or the patient is dyspneic. Additionally, sleep disorders have been described in ALS and some investigators utilize sleep studies to titrate NIV. The Pittsburgh Sleep Quality Questionnaire Index (PSQI) and the Epworth Sleepiness Scale (ESS) are validated questionnaires used to detect sleep disorders. We evaluated the correlation of the PSQI and the ESS with pulmonary function in ALS. 

153 patients were enrolled as part of a multicenter pilot study of nutrition and NIPPV in ALS. All participants completed the ESS and PSQI at their baseline visit along with the ALSFRS-R score, ALS Functional Dyspnea Scale (ALSFDS), Supine FVC (sFVC) and upright FVC (uFVC). The relationship between these measurements and the questionnaires was evaluated using Pearson Correlation Coefficients. 

The mean baseline scores for the scales were: ALSFRS-R 31.2 +/- 9.06, PSQI 7.95 +/- 3.99, and ESS 5.38 +/- 3.78. The number of questionnaires collected were: 87 for ALSFRS-R, 73 for ALSFDS, PSQI and ESS. The ALSFRS-R showed the best correlation with the uFVC (R = 0.76, p<0.001) and sFVC (R= 0.61, p<0.001). The PSQI correlation with uFVC (R = -0.22, p = 0.06) and sFVC (R = -0.14, p = 0.26) was not significant. The ESS correlation with uFVC (R = -0.19, p = 0.11) and sFVC (R = -0.18, p = 0.14) was not significant.

 

The ALSFRS-R scale was most significantly correlated to supine & upright FVC when compared with PSQI and ESS. This suggests that sleep symptoms detected by questionnaires are not as sensitive to declining in respiratory function as changes on ALSFRS-R.

Authors/Disclosures
Ossama Khazaal, MD
PRESENTER
No disclosure on file
Terry D. Heiman-Patterson, MD (Temple University Lewis Katz School of Medicine) Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Heiman-Patterson has received personal compensation in the range of $0-$499 for serving as a Consultant for novartis. Dr. Heiman-Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. The institution of Dr. Heiman-Patterson has received research support from MTPA. The institution of Dr. Heiman-Patterson has received research support from State of Pennsylvania . The institution of Dr. Heiman-Patterson has received research support from ALS Association. The institution of Dr. Heiman-Patterson has received research support from ALS United. The institution of Dr. Heiman-Patterson has received research support from ALS Hope Foundation.
No disclosure on file
Carlayne E. Jackson, MD, FAAN (University of Texas Health Science Center at San Antonio) Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital.
Yvonne Rollins, MD (Heart of the Rockies Regional Medical Center) No disclosure on file
Ashok Verma, MD, FAAN (University of Miami, Clinical Research Bldg) Dr. Verma has nothing to disclose.
Jeremy M. Shefner, MD, PhD, FAAN (Barrow Neurological Institute) Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Uniqure. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clene. Dr. Shefner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cytokinetics. Dr. Shefner has received personal compensation in the range of $0-$499 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for annexon. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurosense. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuvivo. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nura BIo. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prilenia. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for swanbio. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vertex. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Shefner has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Shefner has received research support from NIH. The institution of Dr. Shefner has received research support from Mitsubishi Tanabe Pharma America. The institution of Dr. Shefner has received research support from Amylyx. The institution of Dr. Shefner has received research support from BIogen. The institution of Dr. Shefner has received research support from Cytokinetics. The institution of Dr. Shefner has received research support from IONIS. The institution of Dr. Shefner has received research support from Healey Center for ALS. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a grant review chair with DOD- General Dynamics.
Stephen N. Scelsa, MD (Mount Sinai BETH ISRAEL, Mount Sinai Downtown) No disclosure on file
Daniel S. Newman, MD (Henry Ford Hospital) Dr. Newman has nothing to disclose.
No disclosure on file
Edward J. Kasarskis, MD, PhD, FAAN (UK Healthcare) The institution of Dr. Kasarskis has received research support from Healey Platform Trial Group. The institution of Dr. Kasarskis has received research support from Amylyx . The institution of Dr. Kasarskis has received research support from Alexion. The institution of Dr. Kasarskis has received research support from Woolsey . Dr. Kasarskis has a non-compensated relationship as a Director of ALSA-supported clinic at the University of Kentucky with ALS Association that is relevant to AAN interests or activities.
Edward J. Kasarskis, MD, PhD, FAAN (UK Healthcare) The institution of Dr. Kasarskis has received research support from Healey Platform Trial Group. The institution of Dr. Kasarskis has received research support from Amylyx . The institution of Dr. Kasarskis has received research support from Alexion. The institution of Dr. Kasarskis has received research support from Woolsey . Dr. Kasarskis has a non-compensated relationship as a Director of ALSA-supported clinic at the University of Kentucky with ALS Association that is relevant to AAN interests or activities.